Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019204 (hepatocellular carcinoma)
 71,386 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In summary, of the 460 patients of primary carcinoma of the liver admitted to the University Surgical Unit at the Queen Mary Hospital over a period of 12 years, more than 40% could not be treated, and only 91 of the patients were candidates for curative resection. The cure rate is very small; a 1- to 2-year survival was obtained in 46% of 15 resections. From 1964 to 1969, out of 22 patients with resections, 3 are still alive more than 5 year after the operation. Lin30 reported a 19.1% 5-year survival. When the hepatoma has ruptured and bleeding takes place, surgical treatment is obligatory to control the hemorrhage. Ninety-eight patients underwent a clinical trial of 5 categories: hepatic dearterialization, hepatic arterial cannulation and infusion of 5-FU, hepatic arterial ligation and portal venous infusion of 5-FU, radiotherapy and no treatment. The results show that the advantage of each form of treatment when compared with no treatment is marginal. Thus a gloomy picture of primary hepatoma is held. Since the operative mortality of hepatic resection for a solitary secondary carcinoma of the liver is negligible, it should be done in each instance because a long-term survival may be possible. This is especially true with primary carcinoma of the colon.
 ...
PMID:Techniques and therapies for primary and metastatic liver cancer. 8 19

Gastrointestinal cancer has proved exceedingly resistant to chemotherapy efforts. 5-Fluorouracil (5-FU) accepted as standard treatment, has provided only infrequent and incomplete antitumor effects. Other drugs as the nitrosoureas BCNU and CCNU or Mitomycin C do not match the effectiveness of 5-FU. Improvement in frequency of tumor regression have been recorded for gastric carcinoma with combinations of 5-FU and BCNU and 5-FU, adriamycin and Mitomycin C and for colorectal carcinoma with combination of 5-FU, methyl-CCNU and vincristine. There are also suggestions that such combination chemotherapy may produce increased survival when compared to untreated patients. The combination of 5-FU and streptozotocin in carcinoid tumors or adriamycin in primary hepatoma may be of some effectiveness.
 ...
PMID:[Chemotherapy of gastrointestinal cancer (author's transl)]. 15 93

Twenty-one patients with biopsy-proven hepatocellular carcinoma were treated with oral or intravenous 5-Fluorouracil according to a randomized treatment schedule. Twenty-one patients were evaluable for response and toxicity. The two groups were comparable in distribution of pretreatment characteristics. There were no objective responses in either group. This is the largest reported group of patients with hepatocellular carcinoma treated with 5-Fluorouracil. Toxicity occurred in 46% of patients treated, but was tolerable. In contrast to previous reports, we have found that weekly 5-Fluorouracil given orally or intravenously is not of significant value in the treatment of hepatocellular carcinoma.
 ...
PMID:5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases. 19 41

We established risk factors for high post-resectional recurrence in patients with hepatocellular carcinoma (HCC). They included: (1)Vp (+), (2)IM (+), (3)more than 5 cm in diameter of the main tumor, and (4)gross type except single nodular tumor. Seventy HCC patients in this category were divided into two groups. In group 1, 11 patients prophylactically underwent hepatic arterial infusion chemotherapy after liver resection. Chemotherapeutic agents (MMC, 5-FU, ADM, CDDP) with Lipiodol were administered 4 times a year via Infuse-A-port. The remaining 59 cases served as the control without prophylactic infusion. Two-year survival rate was better in prophylactic group (75%) than in the control (46%, p = 0.063). The two-year disease-free survival was significantly improved in group 1 (40%) compared with that in group 2 (26%, p = 0.019). Based on our data, we suggest that prophylactic arterial infusion chemotherapy can be efficacious in alleviating hepatoma recurrence after liver resection.
 ...
PMID:[Prophylactic chemotherapy by regional arterial infusion in resected hepatoma patients]. 132 14

The effect of multidisciplinary therapy for hepatocellular carcinoma (HCC) was evaluated in 121 resected cases. The 5-year survival was 100% for absolute curative resection (12 cases), 59.1% for relative curative resection (n = 37) and 10.9% for relative non-curative resection (n = 59). However, none of the patients survived for more than 3 years after absolute non-curative resection (n = 13). The non-recurrence in the preoperative TAE groups was different from that in non-TAE groups undergoing absolute and relative curative resection. The 1- and 3-year non-recurrence rates for relative non-curative resection were 92.3% and 53.8%, respectively, for the preoperative TAE group and 56.1% and 28.1%, respectively for the non-TAE group. These data show that preoperative TAE is effective in relative non-curative resection. Functional disturbances of the coagulation-fibrinolysis system in cirrhotic patients were improved after PSE. All patients undergoing hepatectomy after PSE had an uneventful postoperative course, including well-maintained function of the coagulation-fibrinolysis system and a decrease in splenic volume. At 1 year after hepatectomy, cirrhotic patients with critical liver function and poor coagulation-fibrinolysis showed appreciable hepatic regeneration. One patient died of hepatic failure 1 year after the operation. In recurrent HCC, the 1-, 2- and 3-year survival values after reresection were 100%, 75.0% and 25.0%, respectively. The respective values following TAE were 79.0%, 42.0% and 9.0%. Three cases of recurrent HCC were effectively treated, i.e., two patients achieved a partial response and one showed no change, by continuous intra-arterial infusion of 5-FU and lentinan with intermittent one-shot injections of epirubicin using a subcutaneous infusion pump. These three patients are alive at 1 year and 7 months, 1 year and 4 months and 6 months after the treatment, respectively.
 ...
PMID:Significance of multidisciplinary therapy for hepatocellular carcinoma. 133 99

This study was conducted to clarify the role of continuous portal infusion with 5-fluorouracil (FU) from two different standpoints. Experiment I (Assessment of the ability to reduce hepatic metastasis): Male Donryu rats (180-210 g) receiving intraportal inoculation of ascites hepatoma AH 60 C (4 x 10(6) cells) were divided into 3 groups; portal infusion group, venous infusion group and control. 5-FU (20 mg/kg/day) was continuously infused via either the portal vein or the femoral vein with heparin (100 U/kg/day) for 5 consecutive days. The portal infusion group alone showed a significant decrease in hepatic tumor volume on day 21 and prolonged survival time. Experiment II (Evaluation of the immunological effects): Animals without inoculation of AH 60 C were also randomized in the same way as Experiment I. There were no statistical differences among the 3 groups in total leukocyte counts, lymphocyte subpopulations or NK activities in the spleen, whereas hepatic NK activity was significantly decreased in the portal infusion group. Continuous portal infusion with 5-FU is considered effective to prevent lodging of tumor cells in the intra-hepatic portal system but might be disadvantageous for hepatic cellular immunity.
 ...
PMID:[An experimental study on portal infusion of 5-fluorouracil (the second report)]. 153 Mar 1

Four cases of advanced hepatocellular carcinoma patients were treated by intra-portal infusion of 5-FU immediately after surgery. 5-FU at 120-250 mg daily was injected continuously via portal catheter from postoperative day 4 to 21. Two cases with short administration period of 4 days died of recurrence on the residual liver at 9 and 7 months after hepatic resection. Another 2 cases with a total amount of 5-FU at 2,165 mg and 2,250 mg, respectively, survived 4 years 3 months and 4 year 8 months each. Mild leukocytopenia and transient liver dysfunction were found as side effects. Intraportal infusion of anticancer drugs is a promising means to prevent intrahepatic micrometastasis after resection of hepatocellular carcinoma.
 ...
PMID:[Intraportal vein infusion chemotherapy after hepatectomy for hepatocellular carcinoma--preliminary report]. 164 51

A 63-year-old male with four intrahepatic recurrences of surgically resected hepatocellular carcinoma was admitted to our hospital in June 1985. He underwent lateral segmentectomy of the liver in November 1983. Pathologic finding of Edmondson II with liver cirrhosis had been confirmed by the operative specimen. Sizes of four recurrent tumors were assessed by CT as 3.5 x 2.2 cm, 2.6 x 2.2 cm, 2.2 x 2.2 cm and 2.2 x 2.2 cm, respectively. During five years until July 1990, the patient was treated with hepatic arterial infusion of Lipiodol-anticancer drug suspension eight times (total 5-FU 900 mg, ADM 77 mg, MMC 73 mg, and Lipiodol 36 ml) and hepatic arterial chemoembolization of MMC microcapsules one time. In addition, two hepatic arterial infusions of CDDP (total 70 mg) were given and 5-FU (total 10 g) was administered intravenously. Partial response (PR) was obtained for 19 months. Hepatic arterial infusion of Lipiodol-anticancer drug suspension was given only once every 6 months, and he maintained a good quality of life for over four and half years. The man died in July 1990. In general, multiple intrahepatic recurrence of surgical resected hepatocellular carcinoma has a poor prognosis. Therefore it was considered that hepatic arterial infusion of this drug brought about the relatively long survival of more than five years.
 ...
PMID:[A case of recurrent hepatocellular carcinoma after hepatic resection surviving over five years by hepatic arterial infusion of lipiodol-anticancer drug suspension]. 164 91

Twenty-six cases of hepatocellular carcinoma were divided randomly into 3 groups, treated by transcatheter hepatic arterial chemo-embolizations with agents of MMC 20 mg, MMC 20 mg plus lipiodol 10 ml, and MMC 20 mg plus MTXmc 150 mg, respectively, 2 to 3 weeks before surgery. Pathologically, all main tumors in the resected specimens were necrosed to a certain extent, with extensive necrosis in the MMC-MTXmc group, whereas there was no necrosis of cancer cells in tumor capsules, daughter nodules, and intraportal vein emboli. We consider that the transcatheter arterial chemoembolization is effective in reducing tumor burden, but not enough in eradicating all cancer cells, so surgical resection should be carried out whenever resection is possible. For preventing tumor recurrence, direct puncture of the main trunk of the portal vein to infuse 500 mg of 5-FU during operation and injection of MMC 20 mg through a catheter inserted into the hepatic artery 4 weeks after operation is suggested.
 ...
PMID:[Histologic assessment on resected hepatocellular carcinoma specimens with preoperative transcatheter hepatic arterial chemo-embolizations]. 165 Jun 85

The efficacy of combination therapy of anticancer agent-Lipiodol Emulsion for hepatic arterial infusion and regional hyperthermia was studied in 102 patients with nonresectable hepatoma. 5-FU, MFA, CDDP and MFA-CDDP were used as anticancer agents in 13, 44, 26 and 19 patients, respectively. One year survival rates of the each group were 9% (1/13, 5-FU-treated), 29% (12/44, MFA-treated), 43% (11/26, CDDP-treated) and 55% (10/19, MFA-CDDP-treated). Tumor regression was found in one out of 11 (9.1%), 11 out 41 (26.8%), 6 out of 23 (26.1) and 9 out of 19 patients (47.4%), respectively. The regional hyperthermia was particularly efficacious for patients with advanced hepatoma (E3 and E4) and clinical stage II, III; 5 out of 32 patients (16%) receiving arterial infusion and hyperthermia survived more than 1 year while all 15 patients without hyperthermia died within 11 months (p less than 0.01). Our data indicate that repeated arterial infusion of MFA and CDDP Lipiodol Emulsion was most effective for nonresectable liver cell cancer, and the regional hyperthermia prolonged the survival of patients who had advanced hepatoma with poor liver function.
 ...
PMID:[Efficacy of anticancer agent-lipiodol emulsion for hepatic arterial infusion and regional hyperthermia in patients with nonresectable hepatoma]. 165 22


1 2 3 4 5 6 7 8 9 10 Next >>